ACA
WST icon

Aptus Capital Advisors’s West Pharmaceutical WST Stock Holding History

Aptus Capital Advisors’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-905
Closed -$249K – 1791
2025
Q4 		$249K Buy
905
+47
+5% +$12.9K ﹤0.01% 955
2025
Q3 		$225K Buy
+858
New +$209K ﹤0.01% 934
2025
Q1 		– Sell
-725
Closed -$238K – 1506
2024
Q4 		$238K Buy
725
+3
+0.4% +$944 ﹤0.01% 841
2024
Q3 		$217K Buy
+722
New +$221K ﹤0.01% 742
2024
Q2 		– Sell
-520
Closed -$206K – 1235
2024
Q1 		$206K Buy
+520
New +$192K ﹤0.01% 727
2023
Q4 		– Sell
-551
Closed -$207K – 992
2023
Q3 		$207K Buy
+551
New +$213K 0.01% 564

Other funds holding WST

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Aptus Capital Advisors's WST Position: Q1 2026 in Review

Aptus Capital Advisors sold out of West Pharmaceutical (WST) in Q1 2026, closing a stake of 905 shares — an estimated $249K sold.

Aptus Capital Advisors first reported a position in WST in Q3 2023 and held it in 6 quarters. The position peaked at $249K in Q4 2025. 753 funds tracked by Wall St. Rank hold WST as of Q1 2026.

  • Aptus Capital Advisors reported no remaining West Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • Aptus Capital Advisors sold 905 West Pharmaceutical shares in Q1 2026, an estimated $249K.
  • Aptus Capital Advisors first reported a position in West Pharmaceutical in Q3 2023 and held it in 6 quarters.
  • Aptus Capital Advisors's West Pharmaceutical position peaked at $249K in Q4 2025.
  • 753 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2026.

Based on Aptus Capital Advisors's 13F filing for Q1 2026, filed 11 May 2026.